RA Capital Management’s Nautilus Biotechnolgy NAUT Stock Holding History

RA Capital Management’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,436,430	Closed	-$12.6M	–	102
2021 Q4	$12.6M	Hold	2,436,430	–	–	0.22%	73
2021 Q3	$15M	Sell	2,436,430 -35,000	-1%	-$279K	0.21%	67
2021 Q2	$25M	Buy	2,471,430 +1,500,000	+154%	+$16.2M	0.4%	58
2021 Q1	$13.4M	Sell	971,430 -28,570	-3%	-$396K	0.2%	62
2020 Q4	$10.8M	Hold	1,000,000	–	–	0.15%	68
2020 Q3	$10.8M	Buy	+1,000,000	New	+$10.7M	0.2%	58

Other funds holding NAUT

AEPBI

AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

MVG

Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CFM

Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

ACI

Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return

ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return

AEPLI

AH Equity Partners LSV II Menlo Park, California $95.6M AUM 8.86% 1-Year Est. Return

RA Capital Management's NAUT Position: Q1 2022 in Review

RA Capital Management sold out of Nautilus Biotechnolgy (NAUT) in Q1 2022, closing a stake of 2,436,430 shares — an estimated $12.6M sold.

RA Capital Management first reported a position in NAUT in Q3 2020 and held it in 6 quarters. The position peaked at $25M in Q2 2021. 82 funds tracked by Wall St. Rank hold NAUT as of Q1 2022.

RA Capital Management reported no remaining Nautilus Biotechnolgy position as of Q1 2022 after selling out during the quarter.
RA Capital Management sold 2,436,430 Nautilus Biotechnolgy shares in Q1 2022, an estimated $12.6M.
RA Capital Management first reported a position in Nautilus Biotechnolgy in Q3 2020 and held it in 6 quarters.
RA Capital Management's Nautilus Biotechnolgy position peaked at $25M in Q2 2021.
82 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2022.

Based on RA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.